← All news

FROM THE NEWS FEED

Ensysce Biosciences submitted the CYBIO_001 protocol for a Phase 2a trial of CY200 in CRPS Type 1 to the UK MHRA.

2026-09-24 β€’ Blossom Pulse

Article summary

The multicentre, randomised, double-blind, placebo-controlled UK study will assess CY200’s analgesic efficacy, safety and tolerability in adults with CRPS Type 1. The submission marks a step towards starting the Phase 2a trial under MHRA oversight.

Continue to the original publication for the complete article.